|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 187.6 INR | -0.15% |
|
+0.32% | +16.44% |
| 07-02 | Marksans Pharma Gets UK Regulator's Nod for Two Products | MT |
| 05-31 | Transcript : Marksans Pharma Limited, Q4 2024 Earnings Call, May 31, 2024 |
Marksans Pharma Limited announced a private placement of 50,324,324 warrants on January 20, 2023. The transaction will include participation from Mark Saldanha for 1,000,000 warrants and OrbiMed Asia IV Mauritius FVCI Limited for 49,324,324 warrants at a price of INR 74 per convertible warrant including premium. The company will issue warrants on preferential allotment basis.
The transaction has been approved by board of directors of the company.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.44% | 1.02B | |
| +55.35% | 848B | |
| +31.64% | 627B | |
| -0.10% | 363B | |
| +15.47% | 318B | |
| +13.10% | 299B | |
| +15.51% | 243B | |
| +16.72% | 225B | |
| +16.54% | 179B | |
| +4.31% | 167B |
MARKSANS PHARMA LIMITED 
